Kristin VanderPas

About Kristin

Kristin VanderPas' practice focuses on public and private security offerings. She has represented both issuers and investment banks in a variety of equity and debt transactions, including initial public offerings, secondary offerings of common stock and convertible note offerings. Kristin is also a market leader in SPAC M&A transactions, representing both target companies and investors in the de-SPAC process in transactions ranging in value up to $5 billion. Kristin also counsels clients in general corporate and securities law matters.

View full bio

Experience

Viking Therapeutics Announces $632.5 Million Public Offering of Common Stock

March 4, 2024

Cooley advised the underwriters of Viking Therapeutics – a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders – on its $632.5 million public offering of common stock.

Related contacts

Denny Won

Partner, San Francisco

Kristin VanderPas

Partner, San Francisco

Charlie Kim

Partner, San Diego

David Peinsipp

Partner, San Francisco

Valerie Sapozhnikova

Associate, Los Angeles Downtown

Madison (JJ) Meng

Associate, San Francisco

Peter A. Haddad

Associate, San Diego

Natasha Leskovsek

Of Counsel, Washington, DC

Phil Mitchell

Partner, New York

Wyatt Kernell

Associate, New York

Madhuri Roy

Partner, Palo Alto

Randy Sabett

Special Counsel, Washington, DC

Rebecca Ross

Special Counsel, Washington, DC

Xander Lee

Partner, Los Angeles Santa Monica

Related Practices & Industries

Capital Markets

Public Companies

Life Sciences

Healthcare

Life Sciences and Healthcare Regulatory

Tax

CG Oncology Announces Upsized $437 Million IPO

January 29, 2024

Cooley advised the underwriters of CG Oncology, a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, on the pricing of its upsized $437 million initial public offering. Partners Charlie Kim, Denny Won, Kristin VanderPas and David Peinsipp led the Cooley team advising the underwriters.

Related contacts

Charlie Kim

Partner, San Diego

Denny Won

Partner, San Francisco

Kristin VanderPas

Partner, San Francisco

David Peinsipp

Partner, San Francisco

Related Practices & Industries

Capital Markets

Life Sciences

Carmot Therapeutics Enters Definitive Merger Agreement With Roche

December 3, 2023

Cooley advised Carmot Therapeutics, a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, on its definitive merger agreement in which Roche will acquire Carmot.

Related contacts

Jamie Leigh

Partner, San Francisco

Ben Beerle

Partner, San Francisco

Charity Williams

Partner, San Diego

David Peinsipp

Partner, San Francisco

Kristin VanderPas

Partner, San Francisco

Lauren Creel

Partner, Palo Alto

Howard Morse

Partner, Washington, DC

Xander Lee

Partner, Los Angeles Santa Monica

Kathleen O'Neill

Partner, Washington, DC

Ross Eberly

Partner, Los Angeles Santa Monica

Barbara Mirza

Partner, Los Angeles Santa Monica

TJ Graham

Partner, Palo Alto

Christopher Kimball

Partner, Washington, DC

Tracy Rubin

Partner, Palo Alto

Phil Mitchell

Partner, New York

Charlie Kim

Partner, San Diego

Natasha Leskovsek

Of Counsel, Washington, DC

Christine Graham

Special Counsel, London

Stella Sarma

Special Counsel, Brussels

J. Brian Stalter

Special Counsel, New York

Jennifer Shanley

Special Counsel, New York

Grant Schweikert

Special Counsel, Washington, DC

Kristopher Kleiner

Special Counsel, Colorado

Dani Nazemian

Special Counsel, San Diego

Annie Froehlich

Partner, Washington, DC

Karen Tsai

Special Counsel, Washington, DC

Stacey A. Bradford

Special Counsel, Washington, DC

Sangitha Palaniappa

Associate, Palo Alto

Tyler McClure

Associate, San Francisco

Rubin Waranch

Associate, Colorado

Melissa Meza

Associate, San Diego

Jameson Davis

Associate, Boston

Alexander Ellebracht

Associate, Palo Alto

Mor Agam

Associate, New York

Athina Gaki

Associate, Brussels

Andy Zachrich

Associate, San Diego

Dionne A. Thomas

Associate, San Diego

Umer Chaudhry

Associate, Washington, DC

Jane Jun

Associate, Palo Alto

Samara Zaifman

Associate, Palo Alto

Carly E. Gibbons

Associate, Chicago

Claire Norman

Associate, Palo Alto

Anitha Anne

Associate, San Francisco

Kristina Krasnikova

Associate, Palo Alto

Patricia Myers

Paralegal Specialist, Colorado

Loraine Torres

Paralegal Specialist, Colorado

Hitesh Patel

eDiscovery Attorney, Washington, DC

Related Practices & Industries

Mergers and Acquisitions

Life Sciences

Emerging Companies

Venture Capital

Capital Markets

Antitrust and Competition

Life Sciences Corporate Partnering and Licensing

Tax

Compensation and Benefits

Labor and Employment

Healthcare

CFIUS

Cyber/Data/Privacy

Neumora Therapeutics – $250.1 Million IPO

September 15, 2023

Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.